NASA-Based ActivePure® Technology Rapidly Eliminates 99.9% of Airborne SARS-CoV-2 Virus in FDA-Compliant Military Lab Tests

ActivePure Technologies, LLC, announced that its air purifying technology inactivated over 99.9% of highly concentrated airborne SARS-CoV-2 virus in an enclosed setting in just 3 minutes, below detectable levels. Testing of the ActivePure Technology® was conducted by one of the world's top biosafety testing facilities, the University of Texas Medical Branch (UTMB), which primarily tests for the U.S. military and the Centers for Disease Control (CDC).

"These results demonstrate the effectiveness of the technology in a laboratory setting," said Dr. William S. Lawrence, PhD, director of the Aerobiology Services Division at UTMB's Galveston National Laboratory.

ActivePure Technologies foresees widespread use of the technology to reduce the amount of SARS-CoV-2 virus present in the air and on hard surfaces in commercial, residential, and medical settings. ActivePure Technology has been on the retail market as an air purifier for more than 10 years. ActivePure Technologies currently sells about 500,000 ActivePure units annually across all brands and product lines but is seeing an enormous increase in demand from its distributors due to the pandemic.

"ActivePure Technology enables us to go on the offense against airborne coronavirus with real-time elimination of viral particles so we can reclaim the spaces – the gyms, restaurants, diners, theaters, beauty salons and barber shops – that are near and dear to our hearts," said Joe Urso, Chairman and CEO of ActivePure Technologies, LLC. "Unlike conventional, passive, filtration-based air purifiers, ActivePure works immediately and does not require capture or exposure time. It rapidly and continuously fills a room with virus-neutralizing particles that instantly break viruses down to their component parts, rendering them harmless."

"ActivePure surrounds a person with protective virus-inactivating air," Urso added, "which is especially important in a medical setting.  I think of it as a form of Personal Protective Equipment (PPE)."

The Cleveland Clinic is conducting a 2-year study with ActivePure units in its operating rooms to see if the technology can reduce surgical site infections. Daniel Sessler, M.D., chair of outcomes research, said, "The Cleveland Clinic continuously adapts practices to ensure we are providing the safest care for our patients."

"In this deadly pandemic," Urso added, "people must have air they can trust."

The UTMB research was conducted in late November 2020 in a Bio Safety Level (BSL)-3 and -4 laboratory, which studies the world's most deadly pathogens.1 Currently, nearly all BSL-4 analysis is dedicated to Centers for Disease Control and Prevention (CDC) and military testing. According to the CDC, BSL-4 facilities "are used to study agents that pose a high risk of life-threatening disease."2

The tests were done in triplicate, according to FDA guidelines and protocols. Live SARS-Cov-2 virus was sprayed into a test chamber at extremely high concentrations (7+ logs, or over 10 million particles per milliliter).

Within 3 minutes, ActivePure Technology-based Aerus® Pure & Clean and Vollara® Air & Surface Pro units, calibrated to their lowest setting of only 29 cubic feet per minute of air movement, reduced the concentration of the virus to no more than 1.6 logs, a reduction of 99.96%. The lab was able only to measure down to 1.6 logs, so the actual results may have resulted in a 99.99% or greater reduction. 3 The units only used the ActivePure Technology; all other purification technologies in the units were disabled or removed.

Andy Eide, Vice President of Engineering of ActivePure® stated, "We believe the best defense is a good offense. Going out on the attack and proactively neutralizing SARS-CoV-2 viruses is a highly effective way to minimize the amount of virus that reaches your mask or lands on surfaces you may touch." He added, "We manufacture nearly 100 different products with ActivePure, addressing concerns in every imaginable environment from homes to offices, hotel rooms, elevators, and even cars."

A full report by the lab is expected before the holidays, said Urso.

He added, "The November research found that ActivePure technology produces enormous reductions in three minutes, but shorter durations were not tested. We will now be testing efficacy in just 30, 60 and 120 seconds to see how quickly we can achieve similar or better results. And we will be working with the BSL-3 and 4 labs to test other highly contagious pathogens in the future."